Denali

DNLI NASDAQ
18.47
-0.10
-0.54%
Opening 09:46 08/22 EDT
Open
18.61
Prev Close
18.57
High
18.61
Low
18.40
Volume
4.28K
Avg Vol (3M)
312.51K
52 Week High
28.87
52 Week Low
13.78
% Turnover
0.00%
Market Cap
1.77B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Denali DNLI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.
MORE >

Recently

Name
Price
%Change